Business
ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries
ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries.
About this update from Viaderma, Inc.
[{"type":"text","content":"\nViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries\n\nViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries\n\n\nThe Company will Target Countries where Medical and Recreational Cannabis Sales are Legal and Accepted and Scientific Research is Allowed\n\n LOS ANGELES, CA--(Marketwired - March 20, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko has received the Provisional Patent number for two patents pending. The Cannabis Provisional Patent #62466209, a patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution. The second provisional patent #62433964 for enhanced antibiotic and drug delivery for \"Aqueous Topical Applications\" for human and veterinarian uses. The Company plans to continue to expand its (IP) \"Intellectual Property Portfolio\" in 2017.The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted \"Medical Marijuana\" and \"Recreational Use\" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the \"Clinical Studies\" for medical testing such as the United Kingdom and other Asian countries. Company CEO Dr. Christopher Otiko is attending the Diabetic Foot Global Conference (DFCon 20017), at Baylor College of Medicine in Houston, Texas and on Friday 24th of March will present a poster abstract based on seven years of research treating patients with Viabecline. \"In recent studies, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more sev...